Edgar Filing: Lexaria Bioscience Corp. - Form 4

Lexaria Bioscience Corp.										
Form 4 July 19, 2016										
								OMB APPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-0287		
Section 16. Form 4 or	TEMENT OF CH	SECU	RITIES				Expires: Estimated a burden hou response	urs per		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Responses)										
1. Name and Address of Repor BUNKA CHRISTOPHE	Issuer Name and Ticker or Trading nbol xaria Bioscience Corp. [LXRP]				5. Relationship of Reporting Person(s) to Issuer					
(Last) (First)		3. Date of Earliest Transaction (Ch					ck all applicable)			
			h/Day/Year)				X DirectorX 10% Owner X Officer (give title Other (specify below) below) CEO			
			nendment, Date Original Ionth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 			
KELOWNA, A1 V1P1R					Form filed by More than One Reporting Person					
(City) (State)	(Zip)	Table I - Non-	Derivative	Secur	ities Acq	uired, Disposed of	f, or Beneficial	lly Owned		
1.Title of Security (Instr. 3)2. Transaction (Month/Day/Y)	3. e, if Transact Code ear) (Instr. 8)	Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	OwnershipIndiForm: DirectBen(D) orOwnership	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
		Code V	Amount		Price	(Instr. 3 and 4)		D: (
Common Shares						4,971,844	Ι	Private holding company		
Common Shares						7,093,619	D			
Common 07/18/2016 Shares		Р	7,000	А	\$ 0.136	7,100,619	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of
information contained in this form are not
required to respond unless the formSEC 1474
(9-02)

Edgar Filing: Lexaria Bioscience Corp. - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. onNumb of Deriva Securi Acquin (A) or Dispos of (D) (Instr. 4, and	ative ities red sed 3,	(Month/Day/Year) ive les ed ed				8. I De Sec (In
				Code V	(A) ((D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Options	\$ 0.1						12/23/2014	12/23/2019	Common Shares	550,000	
Stock Options	\$ 0.09						06/18/2013	06/18/2018	Common Shares	247,500	
Warrants	\$ 0.23						05/15/2015	05/15/2017	Common Shares	187,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
BUNKA CHRISTOPHER 1924 BIRKDALE AVE KELOWNA, A1 V1P1R7	Х	Х	CEO				

Signatures

Kristin Hamilton 07/19/2016

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.